News

Life Science Start-Up Report 2022 Launched by WAPG and JLL

Boom in start-ups and spin-outs drives growth for UK life sciences as investment almost doubles

● New report shows number of UK life science start-ups in 2016-20 increased by 24% on the previous reporting period to a total of 681, at almost double the rate of ten years ago.

● £20 billion worth of capital is looking to invest in UK life science real estate.

● Total investment in the UK life sciences sector reached a record £4.5 billion in 2021, nearly double the £2.8 billion invested in 2020 (BioIndustry Association).

Strong growth in the US boosts revenue for Boyds

Boyds, the global drug development consultancy, has reported another strong year of growth, with an increase in excess of 20 percent year-on-year in annual revenue in the wake of increased demand for its specialist expertise across the UK, US, and Europe.

Since the opening of Boyds’ US office in Pennsylvania last year, headed by Katy Rudnick, the company has recorded significant growth in US revenue, which now accounts for approximately 30 percent of its total revenue.

April 2022 eNews

Click

Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe

SOMERSET, N.J. – April 6, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K.

Expanded Range of Nucleic Acid Extraction Kits for Pathogens Detection

AMSBIO announce the addition of several new products to its growing range of magnetic bead based nucleic acid extraction kits for pathogen detection.

The MagSi-NA Pathogens MSP (Multiple Sample Pooling) kit sets a new benchmark for automated isolation of nucleic acids (RNA and DNA) from respiratory samples.

One-step ELISA Experiments

AMSBIO announces the launch of the QuicKey Pro™ range of ELISA kits – new easy-to-use assays that require just one step of washing, and one step of sample addition, resulting in a whole experiment taking only 90 minutes.

Compared with traditional ELISA kits, the total procedure time using a QuicKey Pro™ ELISA kit is reduced by 1-2 hours, resulting in significant gains in experimental efficiency.

Crucial Tools for COVID-19 Omicron Research

AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant.

New to the AMSBIO range are recombinant proteins, easy-to-perform assay kits, Omicron pseudotyped lentiviruses and spike neutralizing antibodies for use in functional assays to block SARS-CoV-2 spike protein and ACE2 binding.

Catalent Biologics Completes $30 Million Project for Biopharmaceutical Development and Drug Product Manufacturing in Limoges, France

SOMERSET, N.J. – March 16, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.

BioIVT Acquires Commercial Blood Bank Tennessee Blood Services

Transaction expands BioIVT’s donor network and increases its capacity to provide fresh whole blood, plasma, serum, and red blood cells for drug and diagnostic development

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Tennessee Blood Services (TBS), a commercial blood bank located in Memphis, Tennessee. TBS is FDA-registered to collect whole blood and blood products for diagnostic use by manufacturers and research facilities worldwide.

Evonetix granted patent for technology enabling thermally-controlled DNA synthesis

Cambridge, UK 4th April 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used.

My Account